journal article·2017-04-03

Preparation and characterization of PLGA-β-CD polymeric nanoparticles containing methotrexate and evaluation of their effects on T47D cell line

Fatemeh Gorjikhah, Farid Azizi Jalalian, Roya Salehi, Yunes Panahi, Arash Hasanzadeh, Effat Alizadeh, Abolfazl Akbarzadeh, Soodabeh Davaran

Publisher page

Abstract

Among all cancers that affect women, breast cancer has most mortality rate. It is essential to attain more safe and efficient anticancer drugs. Recent advances in medical nanotechnology and biotechnology have caused in novel improvements in breast and other cancer drug delivery. Methotrexate is an anticancer drug that prevents the dihydrofolate reductase enzyme, which inhibits in the formation of DNA, RNA and proteins which have poor water-solubility. For enhancing the solubility and stability of drugs in delivery systems, we used methotrexate-loaded PLGA- beta-cyclodextrin nanoparticles. The PLGA- beta-cyclodextrin nanoparticles were synthesized by a double emulsion method and characterized with FT-IR and SEM. T47D breast cancer cell lines were treated with equal concentrations of methotrexate-loaded PLGA- beta-cyclodextrin nanoparticles and free methotrexate. MTT assay confirmed that methotrexate-loaded PLGA- beta-cyclodextrin nanoparticles enhanced cytotoxicity and drug delivery in T47D breast cancer cells. These results indicate that encapsulated drugs could be effective in controlled drug release for a sustained period would serve the purpose for long-term treatment of many diseases such as breast cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

,

References (61)

Show source-provided references
1. 10.3109/21691401.2014.92788010.3109/21691401.2014.927880 ↗
2. 10.3109/21691401.2015.111123210.3109/21691401.2015.1111232 ↗
3. Akbarzadeh A, Mikaeili H, Zarghami N, Mohammad R, Barkhordari A, Davaran S. 2012a. Preparation and in vitro evaluation of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with biocompatible copolymers. Int J Nanomedicine. 7:511–526.
4. 10.1186/1556-276X-8-10210.1186/1556-276X-8-102 ↗
5. 10.1186/1556-276X-7-14410.1186/1556-276X-7-144 ↗
6. 10.1186/1477-3155-10-4610.1186/1477-3155-10-46 ↗
7. 10.2147/NSA.S2432810.2147/NSA.S24328 ↗
8. 10.7314/APJCP.2014.15.2.51710.7314/APJCP.2014.15.2.517 ↗
9. 10.1007/s11095-012-0710-z10.1007/s11095-012-0710-z ↗
10. 10.1155/2013/86395110.1155/2013/863951 ↗
11. 10.3390/ijms15091707710.3390/ijms150917077 ↗
12. Baviskar DT, Amritkar AS, Chaudhari HS, Jain DK. 2012. Modulation of drug release from nanocarriers loaded with a poorly water soluble drug (flurbiprofen) comprising natural waxes. Pharmazie. 67:701–705.
13. 10.1016/j.addr.2012.09.03310.1016/j.addr.2012.09.033 ↗
14. Cámara CI, Monzón LMA, Coey JMD, Yudi LM. 2014. Assembly of magnetic nanoparticles at liquid/liquid interface. Catalytic effect on ion transfer process. J Chem Phys. 143:77–83.
15. 10.1371/journal.pone.005733210.1371/journal.pone.0057332 ↗
16. Chung JH, Kim YK, Kim KH, Kwon TY, Vaezmomeni SZ, Samiei M, et al. 2015. Synthesis, characterization, biocompatibility of hydroxyapatite–natural polymers nanocomposites for dentistry applications. Artif Cells Nanomed Biotechnol. 44:277–284.
17. 10.3109/21691401.2014.95510710.3109/21691401.2014.955107 ↗
18. 10.3109/21691401.2014.95363310.3109/21691401.2014.953633 ↗
19. 10.3109/21691401.2015.103190510.3109/21691401.2015.1031905 ↗
20. 10.4236/jeas.2013.3401310.4236/jeas.2013.34013 ↗
21. 10.4236/anp.2014.3100310.4236/anp.2014.31003 ↗
22. 10.1088/0957-4484/24/37/37510110.1088/0957-4484/24/37/375101 ↗
23. 10.1088/1367-2630/14/1/01302510.1088/1367-2630/14/1/013025 ↗
24. 10.3109/21691401.2015.100851010.3109/21691401.2015.1008510 ↗
25. 10.1186/1556-276X-9-39310.1186/1556-276X-9-393 ↗
26. 10.3109/21691401.2014.92256810.3109/21691401.2014.922568 ↗
27. 10.3109/14764172.2015.103904010.3109/14764172.2015.1039040 ↗
28. 10.1016/j.jconrel.2004.10.01510.1016/j.jconrel.2004.10.015 ↗
29. 10.3109/21691401.2015.102962710.3109/21691401.2015.1029627 ↗
30. 10.1016/j.addr.2008.03.01610.1016/j.addr.2008.03.016 ↗
31. 10.1007/s10948-012-1941-210.1007/s10948-012-1941-2 ↗
32. 10.1063/1.368808410.1063/1.3688084 ↗
33. 10.1158/0008-5472.CAN-10-102210.1158/0008-5472.CAN-10-1022 ↗
34. 10.3109/21691401.2014.97180710.3109/21691401.2014.971807 ↗
35. 10.1186/1556-276X-8-6610.1186/1556-276X-8-66 ↗
36. 10.3109/21691401.2015.102962510.3109/21691401.2015.1029625 ↗
37. 10.3109/21691401.2014.97180510.3109/21691401.2014.971805 ↗
38. 10.1161/HYPERTENSIONAHA.108.12141810.1161/HYPERTENSIONAHA.108.121418 ↗
39. 10.1093/abbs/gms03910.1093/abbs/gms039 ↗
40. 10.1158/0008-5472.CAN-04-392110.1158/0008-5472.CAN-04-3921 ↗
41. 10.1016/j.jmmm.2012.08.03410.1016/j.jmmm.2012.08.034 ↗
42. 10.1586/erm.09.1510.1586/erm.09.15 ↗
43. 10.1186/1477-3155-9-5510.1186/1477-3155-9-55 ↗
44. 10.3109/21691401.2014.98280210.3109/21691401.2014.982802 ↗
45. 10.1038/srep0165210.1038/srep01652 ↗
46. 10.7314/APJCP.2014.15.20.869310.7314/APJCP.2014.15.20.8693 ↗
47. 10.1586/14760584.2015.100846010.1586/14760584.2015.1008460 ↗
48. 10.7314/APJCP.2013.14.11.692510.7314/APJCP.2013.14.11.6925 ↗
49. Mulens V, María del Puerto M, Barber DF. 2013. Development of magnetic nanoparticles for cancer gene therapy: a comprehensive review. ISRN Nanomaterials. 2013:646284.
50. 10.1021/acs.molpharmaceut.5b0030410.1021/acs.molpharmaceut.5b00304 ↗
51. 10.7314/APJCP.2013.14.11.659510.7314/APJCP.2013.14.11.6595 ↗
52. 10.3390/nano501006310.3390/nano5010063 ↗
53. 10.1186/1556-276X-8-48510.1186/1556-276X-8-485 ↗
54. 10.1016/j.jmmm.2012.02.07510.1016/j.jmmm.2012.02.075 ↗
55. 10.1016/j.biomaterials.2013.03.06110.1016/j.biomaterials.2013.03.061 ↗
56. 10.4172/2155-6113.100030410.4172/2155-6113.1000304 ↗
57. Sukumar UK, Bhushan B, Dubey P, Matai I, Sachdev A, Packirisamy G. 2013. Emerging applications of nanoparticles for lung cancer diagnosis and therapy. Int Nano Lett. 3:1–17.
58. 10.3322/caac.2119910.3322/caac.21199 ↗
59. Tsuda H. 2010. Risk assessment studies of nanomaterials in Japan and other countries. Asian Pac J Cancer Prev. 11:13–14.
60. 10.1016/j.msec.2006.05.02910.1016/j.msec.2006.05.029 ↗
61. 10.1021/la052063710.1021/la0520637 ↗